Valuation: UCB

Market Cap 5.34TCr 5.96TCr 4.91TCr 4.45TCr 8.32TCr 5,66000Cr 8.47TCr 59TCr 24TCr 2,97700Cr 22TCr 22TCr 9,38900Cr P/E 2026 *
25.3x
P/E 2027 * 21.6x
Enterprise Value 5.36TCr 5.99TCr 4.93TCr 4.47TCr 8.35TCr 5,68500Cr 8.51TCr 59TCr 24TCr 2,99000Cr 22TCr 22TCr 9,43000Cr EV / Sales 2026 *
6.02x
EV / Sales 2027 * 5.18x
Free-Float
61.59%
Yield 2026 *
0.52%
Yield 2027 * 0.54%
1 day+0.50%
1 week+3.19%
Current month+37.20%
1 month+37.20%
3 months+29.68%
6 months+21.71%
Current year+17.94%
1 week 264.8
Extreme 264.8
283.2
1 month 197.45
Extreme 197.45
283.2
Current year 197.45
Extreme 197.45
289.5
1 year 197.45
Extreme 197.45
289.5
3 years 65.4
Extreme 65.4
289.5
5 years 65.4
Extreme 65.4
289.5
10 years 54.84
Extreme 54.84
289.5
Manager TitleAgeSince
Chief Executive Officer 67 01/01/2015
Director of Finance/CFO 60 01/07/2020
Chief Tech/Sci/R&D Officer 59 01/05/2024
Director TitleAgeSince
Director/Board Member 55 01/01/2012
Director/Board Member 67 01/01/2015
Director/Board Member 56 24/04/2014
Date Insider Type Main position Quantity % Market Cap. Importance
15/01/26 Exercice

Executive/Senior Manager

3,000 0.0015%
15/01/26 Exercice

Executive/Senior Manager

3,000 0.0015%
15/01/26 Buy

Director

500 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.50%+3.19%+18.43%+306.06% 5.96TCr
+3.72%+11.75%+68.52%+151.57% 1,22400Cr
+0.62%+4.83%+46.28%+88.08% 66TCr
+1.78%+3.74%+29.85%+108.84% 51TCr
+0.42%+3.20%+54.15%+67.18% 39TCr
+2.96%+3.45%+74.17%+46.35% 36TCr
+1.12%+4.52%+35.30%+58.08% 30TCr
+6.96%+8.86%+11.27%+36.62% 27TCr
+2.15%+7.23%+61.31%+78.97% 25TCr
+4.26%+10.63%+45.74%+121.96% 21TCr
Average +2.37%+3.14%+44.50%+106.37% 42.36TCr
Weighted average by Cap. +2.43%+3.11%+51.25%+102.21%

Financials

2026 *2027 *
Net sales 890.64Cr 994.47Cr 819.25Cr 742.31Cr 1.39TCr 94TCr 1.41TCr 9.77TCr 3.92TCr 50TCr 3.73TCr 3.65TCr 1,56600Cr 990.92Cr 1.11TCr 911.49Cr 825.88Cr 1.54TCr 1,05100Cr 1.57TCr 11TCr 4.36TCr 55TCr 4.15TCr 4.06TCr 1,74300Cr
Net income 218.46Cr 243.93Cr 200.95Cr 182.08Cr 340.34Cr 23TCr 346.72Cr 2.4TCr 961.97Cr 12TCr 915.43Cr 895.96Cr 38TCr 252.65Cr 282.1Cr 232.4Cr 210.57Cr 393.61Cr 27TCr 400.98Cr 2.77TCr 1.11TCr 14TCr 1.06TCr 1.04TCr 44TCr
Net Debt 23Cr 26Cr 21Cr 19Cr 36Cr 2.47TCr 37Cr 255.95Cr 102.75Cr 1.3TCr 98Cr 96Cr 4.1TCr -201.5Cr -224.99Cr -185.35Cr -167.94Cr -313.92Cr -21TCr -319.8Cr -2.21TCr -887.29Cr -11TCr -844.37Cr -826.41Cr -35TCr
Projected Income Statement - Annual - UCB
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
30/26/30 €281.40 +0.50% 2,79,985
29/26/29 €280.00 +3.51% 2,84,311
28/26/28 €270.50 +0.67% 2,93,778
27/26/27 €268.70 -0.59% 3,88,282
26/26/26 €270.30 -0.88% 4,03,103
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - UCB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
280.00EUR
Average target price
291.58EUR
Spread / Average Target
+4.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - UCB